Phathom Pharmaceuticals, Inc. current report, 22 September 2022

Full document

Phathom Pharmaceuticals, Inc. — Form 8-K Summary

Business Context and Reporting Period

Phathom Pharmaceuticals, Inc. is a Delaware biopharmaceutical company. This Form 8-K reports a corporate governance event occurring on September 22, 2022, and was signed on September 26, 2022. The filing does not report quarterly or annual financial results.

Key Financial and Operating Metrics

  • Revenue, profit, cash flow, margins, debt, liquidity, and other financial metrics: not provided in this filing.
  • The filing does not provide financial guidance or updated operating forecasts.

Material Changes Versus the Prior Comparable Period

  • The board appointed James Topper, M.D., Ph.D. as a Class III director, effective September 22, 2022.
  • His initial term expires at the Company’s 2025 annual meeting of stockholders.
  • Dr. Topper was appointed to the nominating and corporate governance committee. He previously served on the Company’s board from January 2018 through May 2021.
  • The board determined that Dr. Topper satisfies applicable Nasdaq independence requirements.

Compensation, Outlook, Risks, and Unusual Items

  • Dr. Topper received an option to purchase 20,000 shares of common stock under the Company’s Non-Employee Director Compensation Program.
  • The option has a 10-year term and vests and becomes exercisable over three years, subject to continued board service.
  • He will receive cash compensation under the same director compensation program and will enter into the Company’s standard director indemnification agreement.
  • The filing states that there were no arrangements or understandings with other persons regarding his selection and no related-party transactions under Item 404(a) of Regulation S-K.
  • No new business risks, contingencies, clinical developments, or management outlook were disclosed.

Important Facts for Investors to Verify

  1. Confirm the terms, exercise price, and accounting treatment of the 20,000-share director option in subsequent filings.
  2. Monitor Dr. Topper’s committee responsibilities and board tenure through the 2025 annual meeting.
  3. Review subsequent periodic filings for financial results, cash runway, liquidity, financing needs, and product-development updates, none of which are addressed here.